Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer

Authors: Martin, Claudio Marcelo, Puello‐Guerrero, Adrián, Mas‐Lopez, Luis Alberto, Campos‐Gómez, Saul, Orlando‐Orlandi, Francisco J., Tejado Gallegos, Luis Fernando, Huggenberger, Reto

Source: Cancer medicine. 12(2):1247-1259

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100172903129.0x000001&indx=1&recIds=ETOCvdc_100172903129.0x000001

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Authors: Kim, Hye Ryun, Awad, Mark M., Navarro, Alejandro, Gottfried, Maya, Peters, Solange, Csőszi, Tibor, Cheema, Parneet K., Rodriguez-Abreu, Delvys, Wollner, Mirjana, Yang, James Chih-Hsin, Mazieres, Julien, Orlandi, Francisco J., Luft, Alexander, Gümüş, Mahmut, Kato, Terufumi, Kalemkerian, Gregory P., Luo, Yiwen, Santorelli, Melissa L., Pietanza, M. Catherine, Rudin, Charles M.

Source: In JTO Clinical and Research Reports November 2023 4(11)

Concurrent chemoradiotherapy with weekly cisplatin in stage III unresectable non-small cell lung cancer (NSCLC): A local experience with LATAM patients.

Authors: Salinas, Carlos, Pinto Negrete, Felipe Eduardo, Saavedra, Maria Paz, Orlandi, Francisco J

Source: Journal of clinical oncology. 39(15 suppl):e20535-e20535

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100174760473.0x000001&indx=1&recIds=ETOCvdc_100174760473.0x000001

Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.

Authors: Sendur, Mehmet Nahit, Reck, Martin, Rodriguez-Abreu, Delvys, Park, Keunchil, Lee, Dae Ho, Cicin, Irfan, Yumuk, Perran Fulden, Orlandi, Francisco J, Leal, Ticiana A., Molinier, Olivier, Soparattanapaisarn, Nopadol, Langleben, Adrian, Califano, Raffaele, Medgyasszay, Balazs, Hsia, Te-Chun, Otterson, Gregory Alan, Xu, Lu, Burke, Thomas A., Samkari, Ayman, Boyer, Michael J.

Source: Journal of clinical oncology. 39(15 suppl):9038-9038

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173219675.0x000001&indx=1&recIds=ETOCvdc_100173219675.0x000001

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.

Authors: Boyer, Michael, Şendur, Mehmet A N, Rodríguez-Abreu, Delvys, Park, Keunchil, Lee, Dae Ho, Çiçin, Irfan, Yumuk, Perran Fulden, Orlandi, Francisco J, Leal, Ticiana A, Molinier, Olivier, Soparattanapaisarn, Nopadol, Langleben, Adrian, Califano, Raffaele, Medgyasszay, Balazs, Hsia, Te-Chun, Otterson, Gregory A, Xu, Lu, Piperdi, Bilal, Samkari, Ayman, Reck, Martin

Source: Journal of Clinical Oncology; 7/20/2021, Vol. 39 Issue 21, p2327-2338, 12p

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

Authors: Rudin, Charles M., Awad, Mark M., Navarro, Alejandro, Gottfried, Maya, Peters, Solange, Csőszi, Tibor, Cheema, Parneet K., Rodriguez-Abreu, Delvys, Wollner, Mirjana, Yang, James Chih-Hsin, Mazieres, Julien, Orlandi, Francisco J., Luft, Alexander, Gümüş, Mahmut, Kato, Terufumi, Kalemkerian, Gregory P., Luo, Yiwen, Ebiana, Victoria, Pietanza, M. Catherine, Kim, Hye Ryun

Source: Journal of Clinical Oncology; 7/20/2020, Vol. 38 Issue 21, p2369-2379, 17p

This result is not displayed to guests.
Login for full access.

Consensus on Treatment and Follow-Up for Biochemical Recurrence in Castration-Sensitive Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries.

Authors: Monteiro, Fernando S. M.^1,2,3 (AUTHOR), Schutz, Fabio A.^1,4 (AUTHOR), Morbeck, Igor A. P.^1,5,6 (AUTHOR), Bastos, Diogo A.^1,7,8 (AUTHOR), de Padua, Fernando V.^1,5,9 (AUTHOR), Costa, Leonardo A. G. A.^1,10 (AUTHOR), Maia, Manuel C.^1,11,12 (AUTHOR), Rinck Jr, Jose A.^1,13 (AUTHOR), Zequi, Stenio de Cassio¹³ (AUTHOR), da Trindade, Karine M.^1,14,15 (AUTHOR), Alfer Jr, Wladimir¹⁶ (AUTHOR), Nahas, William C.¹⁷ (AUTHOR), dos Santos, Lucas V.⁴ (AUTHOR), Ferrigno, Robson⁴ (AUTHOR), da Rosa, Diogo A. R.^1,18 (AUTHOR), Sade, Juan P.¹⁹ (AUTHOR), Orlandi, Francisco J.²⁰ (AUTHOR), de Oliveira, Fernando N. G.^1,21 (AUTHOR), Soares, Andrey^1,16,22 (AUTHOR) dr.andrey@uol.com.br

Source: JCO Global Oncology. 4/15/2021, Vol. 7, p538-544. 7p.

Subject Terms: *PROSTATE cancer, *MEDICAL personnel, *CASTRATION-resistant prostate cancer, *PROSTATE-specific antigen, DEVELOPING countries